The foundation provided support to create a new working capital facility managed by UNICEF to help fund manufacturers to ramp up the production of life-saving Ready-To-Use Therapeutic Food (RUTF). This will enable suppliers to buy raw ingredients, increase staffing, and pay Read More
Program Areas: Maternal & Newborn Child Health
Vedanta Biosciences is creating a new class of drugs to modulate the human microbiome. Vedanta is pioneering the rational design of drugs made of defined consortia of bacteria that are essential dwellers of the gut ecosystem that perform critical functions Read More
Business Wire: Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates
December 24th, 2018 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that it has raised $27 million in a Series C financing Read More
Butterfly has created the world’s first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation’s vision of an ecosystem where hardware, software, data and expertise come together Read More
Sera Prognostics, based in Salt Lake City, UT, is developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications.
Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
Press Release: Kymab secures US $100 million Series C funding
Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More
Press Release: Bill & Melinda Gates Foundation has agreed to join series B financing
Sera Prognostics February 4, 2015 Sera Prognostics, Inc., a women’s healthcare company, today announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. The additional Read More